Madrigal [MDGL] vs Corcept Therapeutics [CORT] Detailed Stock Comparison

Madrigal

NASDAQ
Loading...

Corcept Therapeutics

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Madrigal wins in 7 metrics, Corcept Therapeutics wins in 11 metrics, with 0 ties. Corcept Therapeutics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricMadrigalCorcept TherapeuticsBetter
P/E Ratio (TTM)-20.2378.71Madrigal
Price-to-Book Ratio14.1414.60Madrigal
Debt-to-Equity Ratio17.811.04Corcept Therapeutics
PEG Ratio0.28-26.76Corcept Therapeutics
EV/EBITDA-29.8487.24Madrigal
Profit Margin (TTM)-54.68%18.67%Corcept Therapeutics
Operating Margin (TTM)-22.18%13.72%Corcept Therapeutics
EBITDA Margin (TTM)N/A13.72%N/A
Return on Equity-36.30%21.70%Corcept Therapeutics
Return on Assets (TTM)-18.31%8.36%Corcept Therapeutics
Free Cash Flow (TTM)$-462.03M$195.90MCorcept Therapeutics
1-Year Return103.73%98.81%Madrigal
Price-to-Sales Ratio (TTM)19.1512.97Corcept Therapeutics
Enterprise Value$9.20B$8.95BMadrigal
EV/Revenue Ratio17.8512.50Corcept Therapeutics
Gross Profit Margin (TTM)95.74%98.23%Corcept Therapeutics
Revenue per Share (TTM)$23$7Madrigal
Earnings per Share (Diluted)$-12.63$1.12Corcept Therapeutics
Beta (Stock Volatility)-1.030.46Madrigal
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Madrigal vs Corcept Therapeutics Stock Performance Analysis

Loading Price Chart...

Madrigal
Corcept Therapeutics
Madrigal Stock Overview | Corcept Therapeutics Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Madrigal-1.36%-4.88%-3.86%50.87%40.50%39.04%
Corcept Therapeutics0.52%8.68%26.80%33.71%20.99%80.75%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Madrigal103.73%574.42%248.38%529.55%224.61%26.55%
Corcept Therapeutics98.81%231.81%401.78%2,209.97%2,321.45%1,713.65%

News Based Sentiment: Madrigal vs Corcept Therapeutics

Madrigal

News based Sentiment: POSITIVE

Madrigal Pharmaceuticals reported exceptional revenue growth in Q2 2025 and received numerous positive analyst updates, indicating strong market confidence. While some insider and institutional selling occurred, the overall narrative for the month is positive, driven by the company's financial performance and future growth prospects.

View Madrigal News Sentiment Analysis

Corcept Therapeutics

News based Sentiment: MIXED

October presented a mixed bag for Corcept, with continued strength in Korlym sales overshadowed by lowered revenue guidance and concerning insider selling. The upcoming FDA decisions on relacorilant remain the key driver of potential upside, but near-term challenges and market uncertainty create a complex investment picture.

View Corcept Therapeutics News Sentiment Analysis

Performance & Financial Health Analysis: Madrigal vs Corcept Therapeutics

MetricMDGLCORT
Market Information
Market Cap i$9.87B$9.29B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i284,740733,300
90 Day Avg. Volume i331,680831,183
Last Close$436.28$90.32
52 Week Range$200.63 - $463.63$42.01 - $117.33
% from 52W High-5.90%-23.02%
All-Time High$463.62 (Oct 01, 2025)$117.33 (Mar 31, 2025)
% from All-Time High-5.90%-23.02%
Growth Metrics
Quarterly Revenue Growth13.54%0.19%
Quarterly Earnings Growth13.54%-0.01%
Financial Health
Profit Margin (TTM) i-0.55%0.19%
Operating Margin (TTM) i-0.22%0.14%
Return on Equity (TTM) i-0.36%0.22%
Debt to Equity (MRQ) i17.811.04
Cash & Liquidity
Book Value per Share (MRQ)$31.32$6.04
Cash per Share (MRQ)$35.76$3.25
Operating Cash Flow (TTM) i$-307,412,992$182.19M
Levered Free Cash Flow (TTM) i$-219,782,000$166.88M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Madrigal vs Corcept Therapeutics

MetricMDGLCORT
Price Ratios
P/E Ratio (TTM) i-20.2378.71
Forward P/E i-31.7350.37
PEG Ratio i0.28-26.76
Price to Sales (TTM) i19.1512.97
Price to Book (MRQ) i14.1414.60
Market Capitalization
Market Capitalization i$9.87B$9.29B
Enterprise Value i$9.20B$8.95B
Enterprise Value Metrics
Enterprise to Revenue i17.8512.50
Enterprise to EBITDA i-29.8487.24
Risk & Other Metrics
Beta i-1.030.46
Book Value per Share (MRQ) i$31.32$6.04

Financial Statements Comparison: Madrigal vs Corcept Therapeutics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)MDGLCORT
Revenue/Sales i$137.25M$157.21M
Cost of Goods Sold i$4.51M$2.40M
Gross Profit i$132.74M$154.81M
Research & Development i$44.17M$60.74M
Operating Income (EBIT) i$-79.31M$3.42M
EBITDA i$-69.56M$3.88M
Pre-Tax Income i$-73.24M$9.62M
Income Tax iN/A$-10.93M
Net Income (Profit) i$-73.24M$20.55M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)MDGLCORT
Cash & Equivalents i$183.65M$89.82M
Total Current Assets i$987.98M$438.50M
Total Current Liabilities i$167.24M$143.07M
Long-Term Debt i$118.76M$5.85M
Total Shareholders Equity i$710.64M$683.29M
Retained Earnings i$-1.88B$564.28M
Property, Plant & Equipment i$4.01M$7.69M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)MDGLCORT
Operating Cash Flow i$-81.76M$34.72M
Capital Expenditures i$0$-104,000
Free Cash Flow i$-88.89M$5.02M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricMDGLCORT
Shares Short i4.14M10.81M
Short Ratio i10.9516.33
Short % of Float i0.22%0.14%
Average Daily Volume (10 Day) i284,740733,300
Average Daily Volume (90 Day) i331,680831,183
Shares Outstanding i22.00M105.11M
Float Shares i10.98M86.95M
% Held by Insiders i0.08%0.12%
% Held by Institutions i1.08%0.76%

Dividend Analysis & Yield Comparison: Madrigal vs Corcept Therapeutics

MetricMDGLCORT
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A